Vitamin D and D hormones: Current state and therapy;Vitamin D und D-hormone

Internist

Volumn 39, Issue 6, 1998, Pages 657-667

  Reichel, Helmut ^a  

^a SCHWARZWALD BAAR KLINIKUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

24,25 DIHYDROXYCOLECALCIFEROL; 7 DEHYDROCHOLESTEROL; ALFACALCIDOL; CALCIFEDIOL; CALCIPOTRIOL; CALCITRIOL; COLECALCIFEROL; DAIVONEX; DIHYDROTACHYSTEROL; ERGOCALCIFEROL; TACALCITOL; UNCLASSIFIED DRUG;

AGED; DIET; DRUG METABOLISM; HUMAN; HYPERPARATHYROIDISM; HYPOPARATHYROIDISM; IN VITRO STUDY; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PSORIASIS; REVIEW; RICKETS; SKIN DISEASE; ULTRAVIOLET IRRADIATION; VITAMIN D METABOLISM;

ANIMALS; CALCITRIOL; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 0031806369     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050228     Document Type: Review

References (53)

1. Bouillon R, Okamura WH, Norman AW (1995) Structure-function relationships in the vitamin D endocrine system. Endocrine Rev 16:200-257
2. Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science 240:889-895
3. 3 receptors: gene regulation and genetic circuitry. FASEB J 2:3043-3053
4. Reichel H, Koeffler HP, Norman AW (1989) The role of the vitamin D endocrine system in health and disease. N Engl J Med 320: 980-991
5. 3. Science 190:576-8.
6. 3 In vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treatm Rep69:1399-406
7. 3 treatment and receptor studies in 16 patients with chronic myeloproliferative disorders. Eur J Haematol 39:35-38
8. Cunningham D, Gilchrist NL, Cowan RA, Forrest GJ, McArdle C, Sukop M (1985) Alphacalcidol as a modulator of growth of low grade non-Hodgkin's lymphoma. Br Med J 291: 1153-1155
9. 3 -Open-design study. Calcif Tissue Int 39: 209-12
10. Binderup L, Binderup E, Godtfredsen WO (1997) Development of new vitamin D analogs. In: Feldman D (Hrsg.) Vitamin D, Academic Press, San Diego London, pp. 1027-1043
11. Brown AJ, Slatopolsky ES (1997) Mechanisms for the selective actions of vitamin D Analogs. In: Feldman D (Hrsg.) Vitamin D, Academic Press, San Diego London, pp. 995-1009
12. Mauricio D, Mandrup-Poulsen T, Nerup J (1996) Vitamin D analoguese in insulin-dependent diabetes mellitus and other autoimmune diseases: a therapeutic perspective. Diabetes/Metabolism Rev 12:57-68
13. Lupulescu AP (1996) Hormones, vitamins, and growth factors in cancer treatment and prevention. Cancer 78:2264.-2280
14. Reichel H, Drueke TB, Ritz E (1997) Skeletal disorders. In: Davison AM, Cameron JS, Grünfeld JP, Kerr DNS, Ritz E, Winearls CG (Hrsg.) Oxford Textbook of Nephrology, Oxford, pp. 1954-1981
15. Quarles LD, Lobaugh B, Murphy G (1992) Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:154-150
16. Reichel H (1998) Therapie des renalen Hyperparathyreoidismus mit Vitamin D. Osteologie Forum 4:2-7
17. Ohno J, Kubota M, Hirasawa Y, Suzuki M, Mimura N, Minamikata T (1985) Clinical evaluation of 1α-hydroxycholecalciferol and 1α,25-dihydroxycholecalciferol in the treatment of renal osteodystrophy. In: Norman AW, Schaefer K, Herrath v D, Grigoleit HG (Hrsg.) Vitamin D Chemical, Biochemical and Clinical Endocrinology of Calcium Metabolism, De Gruyter, Berlin, pp. 847-852
18. Berl T, Berns AS, Huffer WE, Hammill K, Alfrey AC, Arnaud CD et al. (1978) 1,25-Dihydroxycholecalciferol effects in chronic dialysis. Ann Int Med 88:774-780
19. 3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Br Med J 282:1919-1924
20. Baker LRI, Muir JW, Sharman VL, Abrams SML, Greenwood RM, Cattell WR et al. (1986) Controlled trial of calcitriol in hemodialysis. Clin Nephrol 26:185-191
21. Fournier A, Moriniere P, Oprisiu R, Yverneau-Hardy P, Westeel PF, Mazouz H et al. (1995) 1-Alpha-hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: Justification and optimal modalities of administration. Nephron 71:254-283
22. Lee WT, Collins JF, Padayachi K, Cundy T (1994) A comparison of oral and intravenous alfacalcidiol in the treatment of uremic hyperparathyroidism J Am Soc Nephrol 5:1344-1348 (1994)
23. Ringe JD (1993) Osteoporose, Diagnose, Prophylaxe und Therapie. Arzneimittel-therapie 11:302-303
24. Hoikka V, Alhava EM, Aro A, Karajalainen P, Rehnberg V (1980) Treatment of osteoporosis with 1-alpha-hydroxycholecalciferol and calcium. Acta Med Scand 207:221-224
25. 3). Endocrinol Jpn 32:305-315
26. 3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone Miner 1:347-357
27. Alioa JF, Vaswani A, Yeh JK, Ellis K, Yasumura S, Cohn SH (1988) Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 84:401-408
28. Ott Sm. Chesnut CH 3d (1989) Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 110:267-274
29. Gallagher JC, Goldgar D (1990) Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized study. Ann Intern Med 113:649-655
30. 3. A three-year prospective study. Clin Rheumatol 11:492-497
31. Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357-362
32. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J (1993) Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitionin. N Engl J Med 328:1747-1752
33. 3. Bone Miner 20:223-234
34. 3 on lumbar bone mineral density and vertebral fractures in patients with post-menopausal osteoporosis. Calcif Tissue Int 54:370-376
35. 3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocr J 43:211-220
36. 3 treatment decreases bone turnover and modulates calcium regulating hormones in early postmenopausal women. Bone 20:557-562
37. Dechant KL, Goa KL (1994) Calcitriol. A review of ist use in the treatment of postmenopausal osteoporosis and ist potential in corticosteroid-induced osteoporosis. Drugs Aging 5:300-317
38. Kruse HP (1985) Behandlung mit Vitamin D, D-Hormonen und synthetischen Analogen. Dtsch Med Wochenschr 110:66-70
39. Jehle PM, Jehle D, Schwarz A, Keller F (1996) Hyperkalzämiebedingte Nierenfunktionsstörungen unter der Therapie mit Dihydrotachysterol. Osteologie Forum 2:66-70.
40. Schmidt-Gayk H (1994) Kongreßbericht Ninth Workshop on Vitamin D. Klin Lab 40:1-4.
41. 3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637-1642
42. Heikinheimo RJ, Inkovaara JA, harju EJ, Haavisto MV, Kaarela RH, Kataja JM, et al. (1992) Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 51:105-110
43. Lips P, Graafmans W, ooms ME, Bezemer PD, Bouter LM (1996) Vitamin D supplementation and fracture incidence in elderly persons. Ann Intern Med 124:400-406
44. Bikle DD (1997) Vitamin D: a calciotropic hormone regulating calcium-induced keratinocyte differentiation. J Am Acad Dermatol 37:S42-S52
45. Staberg B, Roed-Petersen J, Menne T (1989) Efficacy of topical treatment in psoriasis with MC903, a new vitamin D analogue. Acta Derm Venereol 69:147-150
46. Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J et al. (1992) Efficacy and safety of calcipotriol (MC903) ointment in psoriasis vulgaris. J Am Acad Dermatol 27:983-988
47. Ramsay CA, Berth-Jones J, Brundin G, Cunliffe WJ, Dubertret L, van de Kerkhof PC et al. (1994) Long-term use of topical calcipotriol in chronic plaque-type psoriasis. Dermatology 189:260-264
48. Lea AP, Goa KL (1996) Calcipotriol. A review of ist pharmacological properties and therapeutic efficacy in the management of psoriasis. Clin Immunother 5:230-248
49. Thiers BH (1997) The use of topical calcipotriene/calcpotriol in conditions other than plaque-type psoriasis. J Am Acad Dermatol 37:S 69-71
50. Peters DC, Balfour JA (1997) Tacalcitol. Drugs 54:265-271
51. 3 - effects on cell growth regulation in vitro and calcium metabolism in vitro. Pharmacol Toxicol 72:240-244.
52. Van de Kerkhof PC, Werfel T, Haustein UF, Luger T, Czarnetzki BM, Niemann R, et al. (1996) Tacalcitol ointment in the treatment of psoriasis vulgaris: a multicentre, placebo-controlled, double-blind study on efficacy and safety. Br J Dermatol 135:758-765
53. Langner A, Ashton P, van de Kerkhof PC, Verjans H (1996) A long-term multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis. Br J Dermatol 135:3385-3389.